Slide 1: Second Quarter FY 2011 Conference Call and Webinar
Simulations Plus, Inc. (NASDAQ:SLP) Second Quarter FY 2011 Conference Call and Webinar April 18, 2011
Slide 2: Safe Harbor Statement
With the exception of historical information, the matters discussed in this presentation are forward looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ significantly from those statements. Factors that could cause or contribute to such
Slide 3: SLP 2Q11 Highlights
• 2Q11 compared to 2Q10: – 14 th consecutive profitable quarter – 2Q11 sales up 13.5% to Record $3.35 MM from $2.95 MM – Net Income up 41.6% – Pharmaceutical segment sales up 17.7% – Words+ subsidiary sales up 0.7% • 6moFY11 compared to 6moFY10: – Net Income up 37.7% to $1.475 million from $1.071 mi
Slide 4: i we
wo 8! i we ws FF $24 saz a | si 4008 1009 2009 3009 4Q09 1010 2010 sa10 4a10 1011 simulations plus, inc. é
Slide 5: Quarterly Revenues Annual Revenues
Quarterly Revenues Annual Revenues s76 Aree arse Mose sh 0%, "Pharmaceutical Wordst ray "= Phamaceutical ™ Words+ simulations plus, inc. é
Slide 6: Quarterly Revenues
Quarterly Revenues $2.0 : $2.4 Gk S17 $1.4 $14 gus | $14 $14 | 1008 2008 3008 4008 1009 2009 3009 4Q09 1Q10 2a10 3Q10 4ai0 1011 2a11 $1.8 2 & = e simulations plus, inc. é
Slide 7: Gross Margin (consolidated)
Gross Margin (consolidated) 75.6% 78.9% 78.8% 70.4% 73.8% 74.4% 80.0% 67.9% 75.0% 76.3% 77.6% 75.6% 73.6% 77.6%
Slide 8: 1Q08 2Q08 3Q08 4Q08 1Q09 2Q09 3Q09 4Q09 1Q10 Q10 4Q10 1011 2Q11
® < 2 = e 1Q08 2Q08 3Q08 4Q08 1Q09 2Q09 3Q09 4Q09 1Q10 210 3Q10 4Q10 1011 2Q11 simulationsplus, inc. é
Slide 9: Net Income
Net Income $243K $565K $764K $165K $312K $368K $569K $163K $430K $641K $740K $345K $567K $907K
Slide 10: Consolidated Income Statement
2Q11 2Q10 Pharmaceutical software and services revenue 2.621 2.227 Words+ revenue 0.728 0.723 Consolidated revenue 3.349 2.950 Gross profit 2.601 2.249 Gross profit margin 77.6% 76.3% SG&A 0.980 1.089 R&D 0.255 0.252 Total operating expenses 1.235 1.341 Income before income taxes 1.394 0.974 Net inc
Slide 11: Select Balance Sheet Items
February 28, 2011 February 28, 2010 Cash and cash equivalents $8.759 $8.641 Total current assets 12.403 11.448 Total assets $14.785 $13.613 Total current liabilities 1.460 1.294 Total liabilities 2.130 2.152 Shareholders’ equity 12.655 11.461 Total liabilities and shareholders’ equity 14.785 13.613
Slide 12: Share Repurchase Program
Share Repurchase Program • The board of directors approved a second share repurchase program beginning February 2010 for one year (Phase II) • The Phase II program authorized repurchase of up to 1,000,000 shares through February 2011 • The repurchase program is now complete • Over both Phase I and P
Slide 13: Marketing and Sales Program
Marketing and Sales Program • Fundamental industry shift continues – Pharma increasingly utilizing simulation software and modeling tools to increase productivity - steady stream of scientific meetings – Software tools are always evolving, and as the technology advances, new capabilities attract new
Slide 14: Ongoing Enhancements
Ongoing Enhancements * Simulations Plus continues to increase its technological advantage coves) + Version 7.0 was released in August 2010 — a major upgrade + Three new market-expanding capabilities plus numerous features: + Drugito.ciuginteraction (released, nowin betatest for further expansions) +
Slide 15: MedChem Designer - new and powerful!
MedChem Designer - new and powerful! Make copies of a starting molecule, modify them, then click on the AP button and see >120 predicted properties for each of them. Decide in a few seconds whether you want to keep any of them or try different changes to the structure.
Slide 16: Summary
Summary • For the trailing twelve months through February 28: – Revenues = $11.486 million – Net Income = $2.542 million (22.3%) – Earnings/share = $0.16 (16.218 million shares) • Simulations Plus is globally recognized as a leader in our respective market niches, with an outstanding reputation for
Slide 17: simulations plus, inc. é
simulations plus, inc. é